GLP-1 Patient Support Market to Hit $2.85 Billion by 2036 as Onboarding Becomes the Make-or-Break Factor

The market for GLP-1 drug patient support services is growing fast, and the numbers tell a clear story. Fact.MR values it at $545 million in 2026. By 2036, that figure is expected to reach $2.85 billion. That works out to an 18 percent annual growth rate, or about $2.31 billion in new demand over ten years.

Why the surge? A lot of it comes down to how patients start these medications, not just whether they get a prescription.

These drugs require careful dose titration. Patients typically begin on a low dose and increase it gradually. This helps limit side effects like nausea and stomach discomfort. But it also means the early weeks of treatment are fragile. Many patients leave during this window if they do not receive sufficient guidance.

That is exactly why onboarding and injection training now make up the largest chunk of program spending, at nearly 38 percent in 2026. Getting patients comfortable with self-injection and helping them push through initial side effects can make or break long-term adherence.

Digital tools are playing a bigger role here too. Digital-first support hubs now lead the way in program delivery, holding about 35 percent of the market. These platforms combine instructional videos, adherence reminders, and virtual coaching. They also let companies reach far more patients than traditional in-person support ever could, especially as prescriptions for obesity and type 2 diabetes treatment continue climbing.

Pharmaceutical manufacturers are funding most of this. They sponsor roughly 55 percent of patient support programs and account for over 43 percent of end users. That heavy involvement brings scrutiny, though.

The FDA closely watches how manufacturers communicate with patients, and there is a real line between offering genuine support and crossing into promotion. Regulators, including the HHS Office of Inspector General, monitor these programs to ensure they do not run afoul of anti-kickback rules.

Cost remains a major hurdle for patients too. Copay assistance and access support are core parts of most programs, and for good reason. Branded GLP-1 drugs like Ozempic, Wegovy, and Mounjaro carry high list prices, and insurance coverage varies widely.

Medicare coverage is a particular sticking point. The Centers for Medicare and Medicaid Services has faced ongoing pressure to clarify how it handles weight-loss indications, which are treated differently than type 2 diabetes coverage under current policy. All of these medications require a prescription, since dosing and monitoring need clinical oversight.

Geographically, the United States is leading the growth curve, expanding at 17.5 percent annually. Germany and France follow close behind, at 17.1 percent and 16.8 percent respectively. Growth tends to track closely with how many new prescriptions are being written and how much support infrastructure manufacturers have already built out. The U.S. simply has more established distribution networks, which helps these programs scale faster than in most of Europe.

Still, the market has real growing pains. Fragmentation is a common complaint among brand teams. When onboarding, access support, and follow-up care are handled by separate vendors or systems, the patient experience often suffers.

Compliance risk is another concern, especially for manufacturer-run programs, since regulators pay close attention to where support ends and marketing begins. On top of that, proving a program actually improves whether patients stick with treatment is not easy. Attribution remains a genuine challenge for companies trying to measure return on these investments.

Some major players are trying to solve this by consolidating services. Companies like EVERSANA, CareMetx, Valeris, CoverMyMeds, Phil, and AssistRx are building integrated platforms that combine onboarding, copay support, and persistence outreach in one place, rather than offering fragmented pieces.

Brand teams will likely favor integrated, well-governed programs over piecemeal solutions. As GLP-1 receptor agonist prescribing continues to expand across the country, the programs that survive regulatory and payer scrutiny will probably be the ones that can prove they actually keep patients on therapy, not just start them on it.